August 19, 2019 — ViewRay Inc. announced the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer.

HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a new approach to treating recurrent brain tumors. GammaTile Therapy is a U.S. Food and Drug Administration (FDA)-cleared, surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with all types of recurrent brain tumors. The first patient was treated by John Wanebo, M.D., a neurosurgeon and an independent member of the HonorHealth medical staff.

Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution for breast cancer, Lunit Insight MMG. The announcement marks the second approval of its AI solution by Korea MFDS since 2018, when Lunit had gained initial regulatory clearance of its AI software.

An international team of researchers developed a new magnetic resonance imaging (MRI) technique that can capture an image of a brain thinking by measuring changes in tissue stiffness. The results show that brain function can be tracked on a time scale of 100 milliseconds – 60 times faster than previous methods. The technique could shed new light on altered neuronal activity in brain diseases.

Every second counts for stroke patients, as studies show they can lose up to 27 million brain cells per minute. Researchers at The University of Texas Health Science Center at Houston (UTHealth) recently published new findings in Stroke that show patients transported to the hospital by mobile stroke unit (MSU) instead of standard ambulance received a clot-busting procedure an average of 10 minutes faster, which could potentially save up to 270 million neurons per patient.

A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s signal-carrying white matter in children with the disorder, according to a study published in the journal Radiology.1 The same effects were not found in adults with ADHD.

Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.

A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation therapy and bone marrow transplants.

Patient portals can be a one-stop shop for patient access to health records and physicians. They can directly engage patients; provide access to their images; even help providers meet meaningful use requirements.

Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton therapy system. The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now